Compare up to 40 stocks
Compared Stocks: 1 / 40
| Name | Sector | Price | Volume | Market Cap | P/E Ratio | Dividend Yield | Analyst Consensus | Analyst Price Target | Smart Score | Leveraged ETF | Article | Follow |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
 HRTX | General | $0.33 | 7.20M | $71.18M | -3.17 | ― | Hold |
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| HRTX | Heron Therapeutics | 0.33 | -0.68 | -67.66% |
| Name | Price | % Change | |
|---|---|---|---|
| HRTX | $0.33 | -67.66% |
Latest data shows the largest indicative borrow rate increases among liquid option names include: Gorilla Technology Group Inc (GRRR) 98.81% +15.08, Critical Metals Corp (CRML) 58.46% +7.65, Draganfly (DPRO) 21.28%
RBC Capital analyst Leonid Timashev raised the firm’s price target on CorMedix (CRMD) to $15 from $14 and keeps an Outperform rating on the shares. The company announced the acquisition
Needham analyst Serge Belanger raised the firm’s price target on CorMedix (CRMD) to $14 from $12 and keeps a Buy rating on the shares. The firm is adjusting its model
Heron Therapeutics Inc (HRTX) has disclosed a new risk, in the Share Price & Shareholder Rights category. Following the closing of the Asset Sale, Heron Therapeutics Inc. remains subject to
Reports Q3 revenue $35.25M, consensus $37.5M. The company said, “As previously announced, the Company withdrew its full-year 2026 financial guidance in August 2026. The Company is not providing financial guidance
Heron Therapeutics ( ($HRTX) ) has issued an update. On November 8, 2026, Heron Therapeutics agreed to sell substantially all of its assets to CorMedix, excluding its federal tax net
CorMedix (CRMD) and Heron Therapeutics (HRTX) announced that they have entered into a definitive asset purchase agreement under which CorMedix will acquire substantially all of the assets of Heron, and
Heron Therapeutics Inc (HRTX) is scheduled to report 3rd quarter earnings on 11/09/2026, before the market opens. Regarding Q3 estimates, Wall Street analysts expect Heron Therapeutics Inc to post earnings
Latest data shows the largest indicative borrow rate increases among liquid option names include: Stellantis NV (STLA) 4.34% +3.40, PureCycle Technologies (PCT) 46.54% +3.01, GRANITESHARES 2X LONG MU DAILY ETF
Heron Therapeutics ( ($HRTX) ) has provided an update. On September 23, 2026, Heron Therapeutics entered into a multi-product Development and License Agreement with Long Grove Pharmaceuticals and Capstone Development
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| HRTX | Mar 4, 2027TBA | $71.18M | $-0.03 | $34.00M | -0.31 | -3.17 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.
